The numbers coming out of Rocket Lab’s operations read like a growth investor’s wish list. Second-quarter revenue hit $234 million, up 62 percent year over year. The backlog swelled 137 percent to $2.36 billion. A dozen new contracts landed within weeks, including a Viasat mandate for a geosynchronous satellite bus and a slot in the U.S. Space Force’s $981 million NITE-STAR program. The company’s 93rd Electron mission flew flawlessly from Launch Complex 1 in New Zealand on Friday, delivering a ninth Earth-observation satellite for Japanese customer iQPS — the 14th rocket of 2026 to reach orbit.
And yet the stock closed Friday at €62.40, down 12 percent on the week and roughly 53 percent below its 52-week high of €133.80, set in late May. The shares now trade about 13 percent beneath their 50-day moving average. Over twelve months, the equity still shows a 53 percent gain, but the recent slide has investors asking an uncomfortable question: if the fundamentals are this strong, why is the market punishing the stock?
A Sector-Wide Repricing, Not a Company-Specific Breakdown
The most persuasive explanation isn’t unique to Rocket Lab at all. Since SpaceX’s June initial public offering, capital has been rotating out of smaller space names and into the new, more liquid alternative. SpaceX shares themselves fell roughly 36.6 percent in July — a decline that nearly mirrored Rocket Lab’s own drop. That symmetry suggests a sector-wide valuation reset rather than a verdict on any single company’s execution.
The Neutron rocket’s slipping timeline adds a layer of uncertainty, though it’s hardly fresh news. The first stage won’t reach the launch pad until the fourth quarter of 2026, a delay rooted in a failed hydrostatic test of a fuel tank back in January. Rocket Lab acknowledged in early August that a first flight this year is no longer promised. The stock absorbed that blow at the time, and the issue has been a recurring overhang since — a real risk, but one the market has already had ample opportunity to price in.
Buying the Dip, Selling by the Book
What’s striking is who’s stepping in during the weakness. Cathie Wood’s ARK Invest added to its position twice in August — first on the 11th, buying roughly $23.4 million worth of shares across several ETFs immediately after the post-earnings dip, then again on the 18th, picking up 160,890 shares for about $12.7 million. For a prominent growth investor to double down at these levels reads as a conviction signal, not a capitulation.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Insider activity, meanwhile, tells a more nuanced story than the raw data suggests. Over the past six months, Rocket Lab insiders have sold exclusively — CEO Peter Beck disposed of 3.29 million shares, CFO Adam Spice 1.49 million, and General Counsel Arjun Kampani roughly 260,000. But Beck’s sales ran through a Rule 10b5-1 trading plan established back in March, well before the current weakness, and executed automatically rather than by discretionary decision. Such plans are standard tools for diversification and tax planning; reading them as a panic signal ignores the mechanism entirely.
The Operational Engine Keeps Turning
While the market fixates on Neutron’s debut, the core business continues to compound. The Electron cadence remains robust, and the company is collecting orders for the larger rocket regardless of its schedule: a dedicated Neutron mission for Kepler Communications, launching from Launch Complex 3 on Wallops Island, Virginia, no earlier than 2028. That extended lead time suggests customers are willing to bet on the vehicle’s eventual arrival.
The satellite manufacturing arm is also gaining traction. Eight of 17 platforms built under a $143 million MDA Space contract have now reached orbit, where they’ll support Globalstar’s direct-to-device communication services. Mid-August brought the unveiling of GHOST, a transportable launch platform designed to make Electron and the suborbital HASTE rocket operable “anywhere, anytime” — aimed at multi-launch campaigns and national security missions.
The Iridium Communications acquisition is grinding forward on the procedural front. The Hart-Scott-Rodino antitrust waiting period expired on August 12, Rocket Lab filed an S-4 with the SEC, and two days earlier submitted applications to the FCC for license transfers. A new share placement program has also been established, replacing a May program and absorbing its unplaced volume.
The Takeaway
The disconnect between Rocket Lab’s operational trajectory and its share price is real, but the evidence points to market sentiment rather than fundamental deterioration. A sector-wide repricing following SpaceX’s listing, a known and already-discounted Neutron delay, and automated insider sales have all converged to pressure the stock. Meanwhile, institutional buyers are treating the weakness as an opportunity, and the backlog keeps growing. Short-term volatility is likely to persist — but the gap between what this company is doing and what its stock price says about it may be the most interesting metric of all.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from August 24 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 24.
Rocket Lab: Buy or sell? Read more here...
